Category Archives: USTR 301 report

US continue to bully India – Place India again in Special 301 Priority Watch List 2017

Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders across the world.  It points out that India support … Continue reading

Posted in Sec 3 (d), Special 301 report, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, USTR, USTR 301 report | Leave a comment

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

India to US: Will not tighten IPR rules beyond TRIPS mandate

Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report | Leave a comment

Swamy & Subramanian: Comment and context

In a series of tweets, Swamy alleged that “Arvind Subramanian of Washington DC” had urged the US to act against India’s national interests, and called for him to be sacked. Source: The Indian Express | June 23, 2016 After having … Continue reading

Posted in Sec 3 (d), Uncategorized, USTR 301 report | Leave a comment

Please-all IPR policy pleases none

India’s new intellectual property rights (IPR) policy attempts to address concerns of developed countries regarding India’s patent regime, while also protecting public interest, especially that of generic drug producers. However, through this effort of a balancing act, India might have … Continue reading

Posted in IPR, IPR policy, Uncategorized, USTR 301 report | Leave a comment

US pressure on India – MSF’s note on Release of 2016 US Trade 301 Watch List Report

April 27, 2016 – The United States Trade Representative’s (USTR) 2016 “Special 301 Report” was released yesterday. Many countries – including India – are targeted and put on a ‘Priority Watch List’ for using legal tools to protect generic competition … Continue reading

Posted in Compulsory Licensing, Uncategorized, USTR 301 report | Leave a comment